One in five children worldwide is obese, leading to potential growth companies 😺

According to the 2026 Atlas released by the World Obesity Federation on March 4, 20.7% of children aged 5-19 worldwide are currently overweight or obese, up from 14.6% in 2010.

The report states that India has surpassed the United States with 41 million overweight or obese children, ranking second behind China's 62 million.

The coalition is calling for the introduction of a sugar tax, marketing regulations, and improved health standards for school meals, warning that most countries will fail to meet the 2030 goal of halting the rise in childhood obesity.

Based on these facts, we asked AI about US-listed companies that offer GLP-1 and have growth potential 🐱

The main US-listed companies offering obesity drugs are Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO). These companies lead the market with GLP-1 receptor agonists and other obesity treatments as their flagship products.

Notable company in development: Viking Therapeutics (NASDAQ: VKTX): Developing VK2735 (injectable and oral forms), currently in Phase 3 trials.

Pfizer (NYSE: PFE): Acquired Metsera to secure next-generation pipeline; danuglipron also shows progress. Amgen (NASDAQ: AMGN): Holds pipeline including MariTide.

These companies are seeing upward trends in their stock prices, supported by the growth of the obesity drug market, which is projected to reach several trillion yen by 2030.

When you reach the age of doing business, obesity is often seen as a sign of poor self-management and is harmful to health, so demand may increase in the future 🐱

43K Views